In vitro and in vivo growth inhibition of prostate cancer by the small molecule imiquimod

Cited 28 time in scopus
Metadata Downloads
In vitro and in vivo growth inhibition of prostate cancer by the small molecule imiquimod
J H Han; J Lee; S J Jeon; E S Choi; S D Cho; Bo Yeon Kim; D J Kim; J H Park; J H Park
Bibliographic Citation
International Journal of Oncology, vol. 42, no. 6, pp. 2087-2093
Publication Year
Prostate cancer is the second leading cause of cancer death in men worldwide. In the present study, we examined in vitro and in vivo antitumor effect of the small molecule imiquimod, also known as a TLR7 agonist, against prostate cancer. Imiquimod inhibited the growth of mouse (TRAMP-C2) and human (PC-3) prostate cancer cells. Treatment with imiquimod induced cell cycle arrest at the G2/M phase in TRMPA-C2 cells, confirmed by the changes of G2/M checkpoint regulators such as reduction of cyclin B1 expression and increase of phospho-CDC2 and p21 in TRAMP-C2 cells treated with imiquimod. Flow cytometry and western blot analysis revealed that imiquimod induced direct apoptosis in TRAMP-C2 cells via a mitochondrial-dependent pathway. Intratumoral injection with imiquimod reduced significantly tumor growth and increased apoptotic cells in mice subcutaneously implanted with TRAMP-C2 cells. Our results indicate that imiquimod can be an alternative therapeutic for locally generated prostate cancer.
ApoptosisCell cycle arrestImiquimodProstate cancer
Spandidos Publ Ltd
Appears in Collections:
Ochang Branch Institute > Chemical Biology Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.

Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.